Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) COO Sam Boong Park sold 3,403 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $6.08, for a total value of $20,690.24. Following the completion of the transaction, the chief operating officer now directly owns 254,826 shares in the company, valued at $1,549,342.08. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Sight Sciences Stock Down 3.2 %
Shares of SGHT opened at $5.81 on Friday. The business’s fifty day moving average price is $6.50 and its two-hundred day moving average price is $6.23. The firm has a market capitalization of $289.08 million, a price-to-earnings ratio of -5.19 and a beta of 2.71. Sight Sciences, Inc. has a 52 week low of $1.04 and a 52 week high of $8.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50 and a current ratio of 11.01.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. The business had revenue of $21.37 million for the quarter, compared to analysts’ expectations of $21.32 million. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. During the same quarter last year, the business earned ($0.30) earnings per share. On average, analysts predict that Sight Sciences, Inc. will post -1 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the company. Morgan Stanley boosted their price objective on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Lake Street Capital initiated coverage on shares of Sight Sciences in a research report on Wednesday, August 21st. They set a “buy” rating and a $10.00 price target on the stock. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a report on Friday, August 2nd. Finally, Citigroup raised their price objective on shares of Sight Sciences from $6.00 to $6.50 and gave the company a “neutral” rating in a research report on Wednesday, July 10th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $7.25.
Get Our Latest Stock Analysis on Sight Sciences
Sight Sciences Company Profile
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Featured Stories
- Five stocks we like better than Sight Sciences
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Upcoming IPO Stock Lockup Period, Explained
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.